2 mononuclear cells (Hoover et al., 2008), which is consistent with the sharp reduction in
relapses and MRI activity observed in trials for MS (Hauser et al., 2017). If anti-CD20 …

This hypothesis also supports clinical testing of antiviral treatments for MS. While antivirals
targeting EBV have been contemplated in MS for many years, no mechanistic rationale has …

Targeting Epstein-Barr virus to treat MS: Med Skip to Main Content Advertisement Med This
journal offers authors two options (open access or subscription) to publish research This …

Therapy for relapsing–remitting multiple sclerosis (MS) has advanced dramatically despite
incomplete understanding of the cause of the condition. Current treatment involves inducing …

2 are likely to be relevant to the pathogenesis of MS. Importantly, these T-cells reacted to
both latent and lytic EBV antigens, suggesting that latent-lytic EBV cycling boosts T-cell …

Acquiring autoimmunity requires combinatorial fac-tors that arise from both genetic
influences and specific triggering events associated with the environment (Getts et al., 2013; …

EBV is the probable cause of MS and is likely to be driving MS disease activity via latent-lytic
infection cycling. There is evidence that all licensed MS disease-modifying therapies target …

Epstein–Barr virus and multiple sclerosis : Current Opinion in Neurology Epstein–Barr virus
and multiple sclerosis : Current Opinion in Neurology Log in or Register Subscribe to journalSubscribe …

Introduction The etiology of multiple sclerosis (MS) remains unknown. Pathogenesis likely
relies on a complex interaction between multiple environmental, genetic, and behavioral risk …

2 lymphocytes that target the EBV proteins EBNA1, LMP1 and LMP2 (Smith and Khanna,
2023). Allogeneic cells express HLA, so they must be matched to the recipient's HLA to …